Authors

Latest:

Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices

Drs Camidge and Rimel spotlight Dr Rimel’s career journey and the work she does to expand medical care for transgender patients.

Björn Löppenberg, MD

Latest:

Dr. Loppenberg on Benefits of Local Treatment for Metastatic Prostate Cancer

Bob Asinof

Latest:

Bob Asinof on Recruiting Physicians to Private Centers

Bob Asinof, chief executive officer of The Urology Center of Colorado, discusses the challenges of recruiting urologists to their center while competing with larger cancer centers and hospital systems.

Bob Orzechowski, MBA

Latest:

Managing the Growth of NCODA

Bob Orzechowski, MBA, Lancaster Cancer Center, discusses managing the growth of NCODA.

Bob T. Li, MD, MPH

Latest:

Dr. Li on the Limitations of the IMpower010 Trial in Resected Stage IB-IIIA NSCLC

Bob T. Li, MD, PhD, MPH, discusses the limitations of the phase 3 IMpower010 trial in resected stage IB to IIIA non–small cell lung cancer.

Bob Valamehr, PhD

Latest:

Advantages of Off-the-Shelf CAR NK Therapy in B-Cell Malignancies

Bob Valamehr, PhD, chief development officer at Fate Therapeutics, discusses the advantages of off-the-shelf CAR NK therapy in B-cell malignancies.

Bobbie J. Rimel, MD

Latest:

Dr. Rimel on the Importance of BRCA and HRD Testing in Ovarian Cancer

Bobbie J. Rimel, MD, discusses the importance of testing patients with ovarian cancer for homologous recombination deficiency (HRD) or homologous recombination proficiency (HRP), and BRCA mutation status.

Bobby Liaw, MD

Latest:

The Case for Platinum Therapy in Prostate Cancer

The arsenal of therapeutic options for men with castration-resistant prostate cancer has steadily grown as ongoing research uncovers more about prostate cancer biology and resistance mechanisms.

Bone Cancer Research

Bonnie Addario

Latest:

Bonnie Addario on Lung Cancer Support Groups

Bonnie Addario, a lung cancer survivor and founder of the Bonnie J. Addario Lung Cancer Foundation (BJALCF), discusses support groups for patients with lung cancer.

Bonnie Gillis

Latest:

Sequencing Chemo After Radium-223 Safe in mCRPC

Determining the optimal sequencing of novel agents with standard chemotherapy has become a key issue in the management of castration-resistant prostate cancer.

Bonnie Gills

Latest:

Addition of Vorinostat to Bortezomib Achieves Modest Improvement in Progression-Free Survival in Relapsed/Refractory Multiple Myeloma

Vorinostat added to bortezomib improved progression-free survival compared with bortezomib plus placebo in patients with relapsed/refractory multiple myeloma.

Brad Kahl, MD

Latest:

Dr Kahl on Ongoing and Planned Investigations Within the Landscape of MCL

Brad S. Kahl, MD, discusses ongoing and planned investigations within the landscape of mantle cell lymphoma.

Brad Kahl, MD, Washington University School of Medicine

Brad S. Kahl, MD

Brad S. Kahl, MD, is a professor in the John T. Milliken Department of Oncology in the Division of Oncology at the Washington University School of Medicine in St. Louis, Missouri.

Latest:

Dr Kahl on the Evolving Role of BTK Inhibitors in MCL

Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the mantle cell lymphoma treatment paradigm.

Brad S. Kahl, MD, Universi

Brad S. Kahl, MD, University

Brad S. Kahl, MD, UW Carbone Cancer Cente

Brad S. Kahl, MD, Washington University School of Medicine

Latest:

Moving the Dial on CLL Management: Sequencing Strategies and Unmet Needs

Before addressing unmet needs in the management of CLL, Brad S. Kahl, MD, outlines optimal sequencing strategies in the current treatment paradigm.

Bradley A. McGregor, MD

Bradley McGregor, MD, director of Clinical Research for the Lank Center of Genitourinary Oncology at the Dana-Farber Cancer Institute and assistant professor of Medicine at Harvard Medical School, both in Boston, Massachusetts.

Latest:

Dr McGregor on the Outcomes of an Analysis Evaluating the Optimal Dose of Tivozanib in RCC

Bradley McGregor, MD, highlights the outcomes of an exposure response analysis assessing the optimal dose of tivozanib in patients with RCC.